Sunshine Biopharma Inc. SBFM
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
-1.63
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $36.3M | -$6.0M | $12.3M | -$5.5M | $23.0M |
| 2024 | $34.9M | -$5.1M | $10.7M | -$14.2M | $23.5M |
| 2023 | $24.1M | -$4.5M | $8.3M | -$8.9M | $21.2M |
| 2022 | $4.3M | -$26.7M | $1.7M | -$5.4M | $21.6M |
| 2021 | $228,426 | -$12.4M | $110,596 | -$1.8M | $211,662 |
| 2020 | $71,410 | -$2.8M | $45,563 | -$658,490 | -$954,837 |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -1.63 (distress)
- Working capital / assets 0.679
- Retained earnings / assets -2.494
- EBIT / assets -0.207
- Equity / liabilities 3.272
Source: SEC EDGAR filings · CIK 0001402328 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.